GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting
Details are as follows:
"Satraplatin in patients with advanced hormone-refractory prostate cancer: Overall survival results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial," (Abstract #5003), Presenter: A. Oliver Sartor, MD, oral presentation in Chemotherapy for Metastatic Prostate Cancer: New Taxane Combinations and Post-Taxane Options clinical science symposium, W375e, Sunday, June 1, 11:30 AM - 1:00 PM
"Phase I study of satraplatin and docetaxel in solid malignancies," (Abstract #2570), Presenter: Ticiana B Leal, MD, Poster #13B, Developmental Therapeutics: Cytotoxic Chemotherapy general poster session, S Hall A1, Sunday, June 1, 2:00 PM - 6:00PM
"Phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in patients with advanced solid tumours," (Abstract #2560), Presenter: Cristiana Sessa, MD, Poster #11 H, Developmental Therapeutics: Cytotoxic Chemotherapy general poster session, S Hall A1, Sunday, June 1, 2:00 PM - 6:00PM
"Phase I study of oral platinum with concurrent radiation therapy in non small cell lung cancer," (Abstract #7560) Presenter: Hak Choy, MD., Poster #35B, Lung Cancer -- Local-Regional and Adjuvant Therapy general poster session, S Hall A1, Sunday, June 1, 2:00 PM - 6:00PM
The abstracts are available online at www.asco.org.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused on anticancer drugs. GPC Biotech's lead product candidate is satraplatin, an oral platinum compound. The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
GPC Biotech AG
Investor Relations & Corporate Communications Department,
+49 (0) 89 85 65 26 65
In the U.S.:
Laurie Doyle, 1-609-524-1000 X5884
Director, Investor Relations & Corporate Communications
Posted: May 2008